期刊
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
卷 16, 期 1, 页码 S18-S27出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.bbmt.2009.10.016
关键词
GVHD prevention; Methotrexate; Calcineurin inhibitors; Sirolimus; Cyclophosphamide
资金
- NIH [CA142106, CA78902, CA18029, CA15704, HL36444]
In a rapidly developing field, one can always anticipate that different interpretations of similar data will coexist. Stem cell transplanters can be a contentious lot, especially in the absence of controlled randomized trials. Thus, although improvements in the basic understanding of acute graft-versus-host disease (aGVHD) has led to many testable hypotheses in the management of GVHD, there remains little consensus regarding the most effective and least toxic approach to GVHD prevention. In the 1980s, the comparison would have been between cyclosporine-based regimens and ex vivo T cell depletion (TCD). Although ex vivo TCD is still used in some settings, pharmacologic-based therapy and in vivo TCD with serotherapy now predominate. This review is meant to highlight the advantages and disadvantages of the standard of care and assess the prospects for future regimens that may be more effective. (C) 2010 American Society for Blood and Marrow Transplantation
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据